Allos AI, a drug reformulation company, has raised £4 million in a seed funding round led by Oxford Science Enterprises, with participation from Habico Invest and the University of California accelerator Berkeley SKYDECK. The company is focused on reformulating complex small-molecule generic drugs using Causal AI to improve how medicines are delivered and tolerated by patients. The funding will support expansion across formulation development and data science as Allos AI focuses on hard-to-genericise medicines.
Millions of people with chronic, complex conditions rely on specialty drugs that work clinically but can be difficult to tolerate, adhere to, or sustain due to how they are formulated and delivered. Improving an approved drug often requires restarting development and clinical pathways, creating cost, risk, and regulatory barriers that discourage manufacturers from making changes.
Despite clear opportunities to improve delivery, tolerability, and long-term outcomes, most drugs are rarely revisited once they reach the market, including approved generics and early new chemical entities. Patients can remain on suboptimal formulations for years while manufacturers avoid investment due to development uncertainty, even as the global specialty generics market continues to grow.
Allos AI applies Causal AI to model how formulation, dosing, delivery, and patient biology interact to drive clinical outcomes. By identifying reformulation pathways that produce more predictable benefit across stratified patient populations, the company enables smaller, faster, and more interpretable clinical studies while reducing variability between patients.
Using real-world evidence to account for patient and disease heterogeneity upfront, Allos AI reduces development uncertainty, shortens timelines, and lowers the burden of reformulating complex drugs, creating a more predictable path to approval and licensing.
For decades, the pharmaceutical system has treated approval as the finish line, even though for patients it marks the start of a much longer journey. What's been missing is a practical way to keep improving medicines after they reach the market, without relying on workarounds or intuition. With Causal AI, we're building a development platform that allows improvement to be intentional, evidence-driven, and repeatable. Over time, that has the potential to fundamentally change how complex drugs are developed, maintained, and experienced.
Most AI efforts in drug development focus on discovering new molecules, but that's not where the near-term opportunity lies. AI has been pointed at problems that take decades to commercialise, while the biggest barriers in patient care stem from how existing drugs are formulated and delivered. Allos applies Causal AI where it can have immediate impact: improving medicines that already work but remain limited by tolerability, bioavailability, or delivery. By turning reformulation into an evidence-driven engineering discipline, Allos has the potential to reshape how complex generics and high-risk NCE programs advance.
